Background {#Sec1}
==========

Traumatic brain injury (TBI) remains the most common cause of trauma related deaths and disability especially amongst the young individuals (Roozenbeek et al., [@CR42]). Its outcome is determined by two different mechanisms/stages. Primary insult that occurs at the moment of the accident/impact and secondary insult which constitutes the consecutive pathological processes (Prins et al., [@CR41]). The effects of a traumatic brain injury on an individual depends on the type, area of the brain involved and severity of injury. The symptomatic representations are heterogenous and can range from physical effects such as balance and postural problems, headaches and dizziness to cognitive, emotional and behavioral disturbances such as memory problems and anger (Fleminger & Ponsford, [@CR17]).

Acute phase of TBI involves the immediate damage produced from the insult, and the chronic phase may extend for years. Chronic TBI is characterised by inflammation, cell death, and neural dysfunction activated by the primary insult (McKee & Daneshvar, [@CR34]; Werner & Engelhard, [@CR57]). Alterations in cerebral blood flow and oxygenation, edema, excitotoxicity, cell death, disruption of the blood brain barrier, and generalized atrophy is also commonly observed (Acosta et al., [@CR3]).

There have been conventional treatments such as surgical intervention, physical and behavioral therapy, Hyperbaric Oxygen therapy (HBOT), and medical management of associated conditions (Bennett et al., [@CR7]; Xiong et al., [@CR59]). These are focused on reducing the consequences of secondary insult in acute TBI. Due to the brain's limited capacity to regenerate the damaged neurons in chronic injury, cell transplantation may be a useful treatment strategy. In past, few years, it has gained significant attention as a prospective therapeutic option for various neurological disorders (Sharma et al., [@CR47]; Sharma et al., [@CR45]; [@CR46]; Zhang et al., [@CR63]). Different cell types such as bone marrow derived cells, neural stem cells, embryonic cells, umbilical cord blood derived cells, induced pluripotent cells (iPSCs), etc. have been explored (Ul Hassan et al., [@CR53]; Liu et al., [@CR32]; Muotri, [@CR35]; Zhao et al., [@CR66]). The postulated mechanism of cell transplantation includes neuroprotection, neurogenesis, angiogenesis, synaptic remodeling and axonal regeneration which may help repair the neuronal damage in chronic TBI (Xiong et al., [@CR60]).

To assess the safety and feasibility of cell transplantation in chronic TBI, we had previously conducted a pilot study on a small population (*N* = 14) of patients (Sharma et al., [@CR48]). The current study is an extension with larger sample size of 50 chronic TBI patients and a long-term follow up to further establish the efficacy of intervention.

Materials and method {#Sec2}
====================

Ethics statement {#Sec3}
----------------

Selection of patients included in this study was based on the criteria of World Medical Association Helsinki Declaration for Ethical Principles for medical research involving human subjects (World Medical Association, [@CR58]). The protocol of the study was reviewed and approved by the Institutional Ethics Committee. The treatment plan was explained to the patients/ caretakers in detail along with possible adverse events. A written informed consent was obtained either from the patients or their families depending on the patients' cognitive status.

Study design and patient selection {#Sec4}
----------------------------------

An open label non-randomized clinical study was conducted to evaluate the safety and efficacy of intrathecal administration of autologous bone marrow mononuclear cells (BMMNCs) in chronic traumatic brain injury. The study was conducted in a single hospital centre and included 50 patients with chronic TBI.

*Inclusion criteria*: Diagnosed cases of chronic TBI with age above 1 year and patients who were hemodynamically stable were included in the study.

*Exclusion criteria*: The patients were excluded if there was presence of any malignancy, severe liver dysfunction, renal failure, any bone marrow disorder, HIV/HBV/HCV, bleeding tendency, severe anemia \[Hb \< 9\], other acute medical conditions such as respiratory infection, other acute infections and pyrexia and pregnancy or lactation.

Intervention {#Sec5}
------------

The intervention included a combination of cell transplantation and neurorehabilitation. Cell transplantation included administration of autologous BMMNCs intrathecally and neurorehabilitation included a personalised rehabilitation program based on individual needs which comprised of modalities such as occupational therapy, physiotherapy, aquatic therapy, speech therapy and psychological intervention.

### Pre-intervention assessment {#Sec6}

A detailed neuro-evaluation was done for every patient by medical experts. Along with this, hematological, biochemical and serological tests were also performed. Magnetic Resonance Imaging (MRI) of brain with Diffusion tensor imaging (DTI), Electroencephalography (EEG), and Positron Emission Tomography- Computed Tomography (PETCT) brain scans were done before the intervention in all patients. Functional Independence Measure (FIM) was used to evaluate the functional independence of all the patients.

### Bone marrow aspiration and isolation of bone marrow mononuclear cells {#Sec7}

Seventy-two hours and twenty-four hours prior to the procedure, all the patients were administered with Granulocyte Colony Stimulating Factor (G-CSF) injections for stimulation and mobilization of the bone marrow stem cells. Aspiration of bone marrow was carried out under sedation with local anesthesia. 80--100 mL of bone marrow was aspirated from the anterior superior iliac crest depending on the age and body weight of the patient using the bone marrow aspiration needle. The bone marrow was collected in heparinized tubes. Density gradient method was used to separate BMMNCs from the aspirate. Trypan Blue dye was used to calculate the cell viability which was then confirmed using propidium iodide dye on TALI (Invitrogen). The average number of cells injected were 1.28 × 10^8^ with an average cell viability of 97%. CD34+ count was done by fluorescence activated cell sorting (FACS) using CD34 PE antibody (BD Biosciences) and the average count was found to be 256.34 cells/uL.

### Administration of bone marrow mononuclear cells {#Sec8}

Autologous BMMNCs were injected immediately after separation intrathecally between fourth and fifth lumbar vertebrae using spinal needle. The injection procedure is performed under local anaesthesia with or without mild sedation. At the same time, every patient is administered 20 mg/kg body weight methyl prednisolone in 500 ml Ringer Lactate intravenously in order to enhance survival of the injected cells.

Fifteen patients underwent second dose of cell transplantation, 6 months after their first intervention. Protocol for which remained the same. To evaluate the efficiency of multiple transplantations,

To evaluate the efficiency of multiple transplantations, we performed a comparative analysis between patients who underwent single and two doses of BMMNC transplantation.

### Neurorehabilitation {#Sec9}

Immediately after cell transplantation, every patient underwent a personalized neurorehabilitation program which included, occupational therapy, physiotherapy, psychological therapy, speech therapy and aquatic therapy. The patients were also advised to continue neurorehabilitation after discharge and were given a home program for the same.

Study analysis {#Sec10}
--------------

Patients were followed up at regular intervals post intervention and a detailed neurological assessment was performed at follow up.

### Percentage analysis {#Sec11}

Percentage analysis was performed to study improvements in each symptom. Overall improvements were categorised as mild, moderate and significant based on the grading system which we designed for the study. The grading system devised to evaluate the functional outcome in every individual as follows: *Mild improvement*: improvement seen in less than 30% symptoms;*Moderate improvements*: improvements seen in 30--60% symptoms;*Significant improvements*: improvements seen in more than 60% symptoms along with change in FIM scores

### Outcome measures {#Sec12}

FIM was used to monitor changes in functional dependence of patients while performing activities of daily living. It was measured before intervention and at follow up.

### PET CT scan of the brain {#Sec13}

18 F-FDG PET CT was used as a monitoring tool to assess the outcome of cell transplantation in chronic TBI. It was performed before the intervention and a comparative PET was performed 6 months later to study the metabolic changes occurring in the brain due to the intervention. Consent was obtained from 10 patients for repeating PET-CT scan of the brain 6 months after intervention.

Statistical analysis {#Sec14}
--------------------

Statistical analysis was performed using IBM SPSS version 2.0 software. The difference between pre-intervention and post- intervention FIM scores were compared using Wilcoxon matched-pairs signed rank test to find its significance. The significance level was pre-determined at *p* ≤ 0.05.

### Factors affecting the outcome of cell transplantation {#Sec15}

A detailed subgroup analysis was done to determine the effect of various factors such as age at intervention (\< 18 years and \> 18 years), number of doses, time since injury and severity of injury based on Glasgow Coma Scale (GCS) on the outcome of cell transplantation.

### Adverse event monitoring {#Sec16}

During the stay in the hospital and after discharge, signs and symptoms of any major or minor adverse events were monitored at regular intervals to establish short-term and long-term safety. Adverse events were grouped as procedure related and cell transplantation related. Fever, spinal headache, nausea, diarrhea, vomiting, pain at the site of aspiration and injection, anesthesia related issues and minor allergic reactions were considered as minor procedure related adverse events which could be managed by medication immediately. Hematoma at the site of aspiration and injection, bleeding at the site of aspiration or injection, local infection at the site of injection or aspiration, meningitis, respiratory distress, major allergic reactions were considered as major procedure related adverse events and new seizures or increased seizure intensity /frequency were considered as major cell transplantation related adverse events.

Results {#Sec17}
=======

Demographic analysis {#Sec18}
--------------------

### Description of the sample {#Sec19}

The total population included in the study was 50 including 42 (84%) males and 8 (16%) females. The age of the population ranged from 7 to 64 years with a mean age of 29 years (Table [1](#Tab1){ref-type="table"}). Table 1Demographical data of the patientsTotal patients*n* = 50SexMale42Female8AgeAvg. age (in years)29.4\< 18 years10\> 18 years40Cause of traumaRoad Traffic Accident (RTA)40Others10Duration since injury\< 5 years32\> 5 years18Severity based on CGSMild27Moderate16Severe7History of seizuresPresent16Absent34

Percentage analysis {#Sec20}
-------------------

### Overall improvements based on the grading system {#Sec21}

Overall 90% patients i.e. 40 out of 50 patients showed improvement after cell transplantation. Based on the grading system as described above, 25 (50%) showed significant improvement, 8 (16%) showed moderate improvement, 13 (26%) cases showed mild improvement, 4 (8%) showed no improvement (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Graph representing overall improvements in TBI after cell transplantation

### Symptomatic improvements {#Sec22}

Average follow up was 22 months (range: 3--71 months). During the symptomatic analysis, patients showed improvement in balance, voluntary control, memory, oromotor skills, lower limb activities, ambulation, trunk & upper limb activity, speech, posture, communication, psychological status, cognition, muscle tone, coordination, activities of daily living (ADLs) (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Fig. 2Graph demonstrating symptomatic improvements in patients with chronic TBI after cell transplantationTable 2Percentage analysis for each symptomatic improvement in chronic TBI patientsSymptomsAffectedImprovedPercentage improvementAttention and concentration332884.84ADLs463678.26Balance422969.04Muscle Tone422866.66Speech442965.9Orientation322062.5Voluntary Control472961.7upper limb activity462758.69Truncal Activity472757.44Posture442556.81Ambulation422354.76Cognition361952.77Coordination422150Standing422150Memory301446.66Oromotor Skills371745.94Problem Solving331545.45Bowel and Bladder Management351440Sensation291137.93

### Outcome measures {#Sec23}

30 out of 50 (60%) patients showed improved FIM scores after intervention at follow up. On Wilcoxon signed rank test, the change in FIM scores was found to be significant at *p* ≤ 0.05 with *p*-value 0 (Table [3](#Tab3){ref-type="table"}). Table 3Result of statistical analysis of FIM scoresScaleMean score before cellular therapyMean Score after cellular therapyZ ValueSignificanceFIM55.8462.2−4.7821Significant

PET CT scan brain {#Sec24}
-----------------

On comparing the PET CT scan brain performed before and 6 months after intervention in 10 patients, improved brain metabolism was recorded. It was observed that the metabolic activity in frontal lobe, mesial temporal structures (amygdala, hippocampus), parietal cortex, occipital lobe, thalamus and cerebellum had improved. These changes in the metabolic activity correlated with the clinical and functional improvements demonstrated by these patients (Table [4](#Tab4){ref-type="table"}). Table 4Areas of brain showing increased metabolism in PET CT scan corresponding to the functional improvements in ten patientsPatientsArea of the brain showing improved metabolismSymptomatic improvement1Temporal, parietal lobe, left mesial temporal, bilateral cingulate, amygdala, cerebellum, basal gangliaEmotion, attention, cognition, memory, coordination, balance, voluntary motor control, learning, cognition, speech, memory2Cerebellum, thalamus, occipital lobe and basal gangliacoordination, balance, voluntary motor control, learning, Vision and perception, Motor control, sensory functions3Frontal lobes, parietal lobes, l occipital lobes.Vision and perception, Planning, Long term memory, emotions, speech, problem solving, Movement, orientation4Parieto-Occipital AreasCognition, speech, sensation, orientation and visual perception5Cingulate Gyri, Amygdala, Frontal, temporal lobeEmotional responses, memory, attention, Planning, Long term memory, emotions, speech, problem solving6Basal ganglia, temporal cortex, cerebellum, bilateral thalamusCoordination, balance, voluntary motor control, learning, Motor control, sensory functions7Cerebellum, basal gangliaCoordination, balance, voluntary motor control, learning, Motor control8Bilateral cerebellum, right frontal, parietal, temporal and occipital cortex, right basal ganglia and right thalamusEmotion, attention, cognition, memory, co-ordination, balance, voluntary motor control, learning, cognition, speech, memory, sensory functions9Bilateral cerebellum, vermis, cingulate regions, Right Superior parietal gyrusVoluntary movements, posture, balance, attention span, cognition, emotional response10Cingulate cortex, basal ganglia and cerebellumEmotional responses, memory, problem solving, co-ordination, balance, voluntary motor control,

Factors affecting the outcome after the intervention {#Sec25}
----------------------------------------------------

### Age {#Sec26}

On performing age-wise analysis of FIM scores, it was observed that more patients in the age group of \< 18 years (paediatric) showed improvement as compared to patients in the age group of \> 18 years (adults) (Table [5](#Tab5){ref-type="table"}). Table 5Percentage improvement in FIM scores after cell transplantation based on different factors influencing the outcome of interventionNo. of patients showing improved FIMPercentage improvement**Age at intervention**Less than 18 years (*n* = 13)1076.92Above 18 years (*n* = 37)2054.05**Multiple Doses**Single dose (*n* = 35)2160Two doses (*n* = 15)960**Time since injury**0--5 Years (*n* = 32)2165.625 Years and above (*n* = 18)950**Severity based on GCS**Mild (*n* = 27)1762.96Moderate (*n* = 16)956.25Severe (*n* = 7)457.14

### Multiple doses {#Sec27}

In our study, 15 patients underwent second dose of cell transplantation. On analysing the outcome on FIM, there was no difference observed in the group which underwent single dose as compared to the group of patients who underwent a second dose of transplantation (Table [5](#Tab5){ref-type="table"}).

### Time since injury {#Sec28}

On analysing the effect of time since injury, it was found that patients who underwent cell transplantation within 5 years from their injury showed better outcome on FIM scale (Table [5](#Tab5){ref-type="table"}).

### Severity of injury based on GCS {#Sec29}

On analysing the effect of severity of injury on the outcome of intervention, it was found that patients who were categorised as mild TBI based on CGS showed better outcome as compared to those who were moderate and severe TBI (Table [5](#Tab5){ref-type="table"}).

Adverse events {#Sec30}
--------------

During the hospital stay, only 1 patient complained of headache and vomiting. There were no anesthesia related side effects witnessed in any of the patients. Within 3 months of the intervention, 2 patients had an episode of seizure as an adverse event, which was managed with medications. Both patients had abnormal EEG and 1 out of 2 had previous history of seizures and was on antiepileptics.

Discussion {#Sec31}
==========

Chronic TBI is a complex and heterogeneous disease process ranging from the initial damage at the time of trauma to the consecutive destructive secondary damage (Hartings et al., [@CR23]).Cell transplantation has shown potential to repair neuronal damage occurring in chronic TBI through neurorestorative and neuroprotective mechanisms. It utilizes the neurogenic capacity of stem cells to help in restoration of the damaged brain (Tajiri et al., [@CR51]). The regenerative capacity of stem cells has been established in preclinical studies of TBI (Tajiri et al., [@CR51]; Lee et al., [@CR28]; Guo et al., [@CR22]; Anbari et al., [@CR5]; Acosta et al., [@CR2]). Various studies involving animal models of TBI have shown improved motor function, cognitive function and behavioural outcome after cell transplantation using human fetal and embryonic-derived NSCs, blood, umbilical cord, placental, bone marrow progenitor, and mesenchymal stem cells. These improvements occur due to secretion of neurotrophic factors by these cells along with increased angiogenesis and reduced astrogliosis (Wennersten et al., [@CR56]; Yan et al., [@CR62]; Kim et al., [@CR26]). Safety and feasibility of cell transplantation has also been established clinically. Zhang et al. studied the safety of bone marrow derived mesenchymal stem cells in 7 patients with TBI. They found that a combined procedure of intracranial and intravenous injection of autologous mesenchymal cells was safe and resulted in significantly improved neurological functions (Zhang et al., [@CR65]). Similarly, Cox et al. and Liao et al. reported intravenous administration of autologous bone marrow mononuclear cells in children with severe traumatic brain injury to be safe with positive outcomes (Cox Jr et al., [@CR12]; Liao et al., [@CR31]). Our previously published pilot study also demonstrated safety and feasibility of autologous bone marrow mononuclear cell transplantation in 14 chronic TBI patients (Sharma et al., [@CR48]). To further assess efficacy in larger population and for a long-term follow up, we conducted the presented study.

Mechanism of action of bone marrow mononuclear cells in chronic TBI {#Sec32}
-------------------------------------------------------------------

Clinical application of bone marrow mononuclear cells (BMMNCs) is relatively safe and feasible (Zhang et al., [@CR63]; Zhang et al., [@CR65]; Savitz et al., [@CR44]; Nguyen et al., [@CR38]). They are a comprehensive cell population of various cell types like lymphocytes, monocytes of hematopoietic lineage, progenitor cells, mesenchymal cells, very small embryonic like (VSELs) stem cells and endothelial progenitor cells (EPCs) (Natividad Cuende et al., [@CR37]). It has been observed that use of BMMNCs is more successful than the sub fractionated cell preparations (Lawall et al., [@CR27]). The implanted BMMNCs follow the chemotactic pathway of SDF-1/CXCR4 and migrate to the site of injury and promote functional recovery (Li et al., [@CR29]). BMMNCs multiply and differentiate into various cells such as neural cells and oligodendrocytes and promote neuroregeneration (Sanchez-Ramos et al., [@CR43]). In TBI, myelin loss and axonal damage causes disruption of signal transduction. The oligodendrocytes help in remyelination and consequently repair the neural connections (Xu et al., [@CR61]). BMMNCs protect the white matter degeneration and capillary breakdown secondary to acute injury (Park et al., [@CR39]). They secrete various trophic growth factors such as nerve growth factor (NGF), glial derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), which help in neuroprotection and inhibition of neuronal toxicity (Chen et al., [@CR11]). These strategies limit secondary tissue loss and improve functional outcome in patients.

TBI also triggers a cascade of immunological and inflammatory tissue responses including depolarization of nerve terminal membrane and excessive release of excitatory neurotransmitters (Werner & Engelhard, [@CR57]). The initial inflammatory response after TBI results in neuronal injury and activation of microglia resulting in the production of proinflammatory cytokines and neurotoxic chemicals (Hernandez-Ontiveros et al., [@CR25]; Town et al., [@CR52]). Cell transplantation simulates brain repair processes and has an anti-inflammatory and neuroprotective effect on the damaged cells (Shoichet et al., [@CR49]). It has the potential to curtail the neuronal cell death and the prolonged secondary inflammatory response, which results in increased recovery in both cognitive and motor functions (Acosta et al., [@CR4]; De la Pena et al., [@CR13]). Bone marrow cells also secrete exosomes which are extracellular vesicles. Their therapeutic significance has been studied in animal models of TBI (Zhang et al., [@CR64]). Exosomes may aid in functional recovery by inducing neurogenesis, angiogenesis and reducing inflammation (Feng et al., [@CR15]). The consequent release of vasoconstrictors (prostaglandins and leukotrienes), microvascular dysfunction, the blood--brain barrier lesion, and the edema formation after TBI further reduces tissue perfusion and aggravates secondary brain damage (Prabhakar et al., [@CR40]). The neuro-restorative effects exerted by the BMMNCs like angiogenesis, neovascularisation, production of growth factors, and paracrine effects enhances the tissue metabolism and thereby improves information processing in the damaged brain areas.

Route of administration {#Sec33}
-----------------------

The identification of the appropriate route of administration of cells is a crucial step, as the efficacy of intervention depends on the effective delivery of cells to the site of lesion. Direct intracerebral injection is an invasive procedure which may cause secondary damage (Abe et al., [@CR1]). Intravenous transplantation is a minimally invasive procedure, however, the transplanted cells get trapped in the pulmonary passage and only few cells reach the target tissue (Fischer et al., [@CR16]). Intrathecal route of administration provides the maximum homing capacity to the injected cells at the affected brain areas (Chen et al., [@CR10]).

Role of rehabilitation {#Sec34}
----------------------

As a part of the protocol, all the patients were given standard rehabilitation along with cell transplantation. It augments the therapeutic potential of the intervention. Enhanced proliferation of cells and increased mobilization of hematopoetic cells and erythropoetic cells in peripheral blood are some of the mechanisms triggered due to exercise (van Praag et al., [@CR54]). Increase in angiogenesis and thus oxygen supply to the damaged areas of the brain is another aspect of exercise that improves the cognitive function. Regular exercise upregulates the chemokine guided SDF1/CXCR4+ pathway of homing and migration of stem cells and exerts an anti-inflammatory effect on the body (Bherer et al., [@CR8]; Gomez-Pinilla & Hillman, [@CR20]).

Clinical outcome {#Sec35}
----------------

Overall 92% patients showed improvements in various symptoms such as balance, voluntary control, memory, oromotor skills, lower limb activities, ambulation, trunk & upper limb activity, muscle tone, coordination, speech, posture, communication, psychological status, cognition, attention and concentration and ADLs. FIM was used to assess the functional status of the patients based on the level of assistance they required for their ADLs. Motor and cognitive impairment are the two most common outcomes of TBI (Godbolt et al., [@CR19]; Breceda & Dromerick, [@CR9]). FIM effectively evaluates patient's functional abilities extensively covering cognitive and motor domains (Shukla et al., [@CR50]). In this study, 60% patients showed improved FIM score suggesting improvement in ADLs such as bowel and bladder control, transfers, locomotion, communication, social cognition and self-care activities. Studies have shown that functional recovery after cell transplantation and neurorehabilitation could be attributed to endogenous plasticity, formation of new synapses and neural circuits which reorganize the damaged areas of the brain (Li & Chopp, [@CR30]). New learning helps the brain establish new pathways and connections which enhances the information processing in these patients.

Findings of PET CT scan brain {#Sec36}
-----------------------------

We used PET CT to monitor the outcome of cellular transplantation. Only 10 patients consented to perform a repeat PET CT for comparative analysis. \[18F\] Fludeoxyglucose (FDG PET) is a valuable tool in monitoring changes associated with early metabolic dysfunction and cognitive deficits in TBI. PET imaging provides exquisite sensitivity and information regarding changes in brain metabolism after TBI. Few studies have explored FDG-PET in TBI with varying degrees of sensitivity to detection at acute, subacute, and chronic phases of injury. These studies have shown reduced metabolism in the frontal, temporal, thalamic and cerebellar regions after the trauma (Granger et al., [@CR21]; Giza & Hovda, [@CR18]; Nakashima et al., [@CR36]). These areas of the brain are directly responsible for behavioural and cognitive deficits in these patients. In this study, reduced metabolism was seen in frontal, temporal, parietal, mesial temporal, occipital, basal ganglia and cerebellar regions after the accident. These areas showed improved brain metabolism in the 10 patients who underwent PET CT scan brain 6 months after cell transplantation. These improvements correlated to the symptomatic changes observed in the patients at follow up. Similar results were published by Vaquero et al., wherein they demonstrated improved brain metabolism in the frontal, temporal, parietal, basal ganglia and cerebellar regions after intrathecal administration of autologous mesenchymal stromal cells which further resulted in clinical improvement in patients with diffuse axonal injury (Vaquero et al., [@CR55]).

Factors affecting the clinical outcomes {#Sec37}
---------------------------------------

Various factors can affect the outcome of cell transplantation in chronic TBI. We analyzed the factors such as age, multiple doses of transplantation, time since injury and severity of injury, to study the effect of these on the efficacy and outcome of cellular transplantation.

### Age at intervention {#Sec38}

To study the effect of aging on the recovery of the chronic TBI patients after the cell transplantation, we compared the outcome on the objective scales in pediatric (\< 18 years) and adult (≥ 18 years) patients.

It was observed that the pediatric patients demonstrated better improvements in the objective scale than the older patients (≥ 18 years). This outcome could be a result of the fact that brain plasticity is greater in the younger age and is malleable. The neurotransmitter interactions in neural circuit may also change as a function of age. For e.g. glutamate which has an important role in the maintenance of cellular function and apoptosis, reduces with age (Diaz-Arrastia et al., [@CR14]). Intervention after injury at a younger age is likely to be more effective and can change the recovery trajectory in chronic TBI patients (Mahncke et al., [@CR33]; Hebbeler et al., [@CR24]).

### Number of doses {#Sec39}

To evaluate the efficiency of multiple transplantations, we performed a comparative analysis between patients who underwent single and two doses of BMMNC transplantation. In the present study, 60% of patients from both the groups showed improvement in FIM score. The number of doses did not affect the outcome of transplantation.

### Time since injury {#Sec40}

76.66% patients who underwent cell transplantation within 5 years of their injury showed improvement in their FIM score as compared to those who took intervention after 5 years of their injury. This could be because when the chronicity of the injury increases, it makes injury repair more difficult.

### Severity based on GCS {#Sec41}

Patients were categorised on severity based on the GCS. In this study, the outcome of intervention in patients with mild TBI was better as compared to moderate and severe TBI. 62.96% patients with mild TBI showed change in their FIM scores which indicate better functional recovery.

Adverse events monitoring {#Sec42}
-------------------------

In this study, all the patients were monitored for procedure related and cell transplantation related adverse events during their hospital stay as well as after discharge.

### Procedure related adverse events {#Sec43}

The adverse events associated with bone marrow aspiration and/or injection via lumbar puncture were categorized as procedure related adverse events. These included spinal headache, nausea, diarrhea, vomiting, pain or bleeding at the site of aspiration /injection, fever amongst others. Patients were also checked for anesthetic complications and allergic reactions. Only 1 patient complained of headache which was treated using medications.

### Cell transplantation related adverse events {#Sec44}

Two patients had an episode of seizures which was managed with medication. They both had an abnormal EEG before the intervention and 1 of them had previous history and was on antiepileptics. Occurrence of seizures did not affect the outcome of the intervention in these patients. The episode of seizures could be due to abnormal innervation in the neural circuits or activation of the epileptogenic foci during the process of neurogenesis (Banerjee et al., [@CR6]). The longest follow up of this study population was 71 months and there were no cell related adverse events recorded indicating long-term safety.

Limitations {#Sec45}
-----------

One of the major limitations of the study was lack of control group to study the effect of cellular transplantation. However, all the chronic TBI patients were on rehabilitation before the intervention and their improvements were plateaued and did not show functional recovery. But after cellular transplantation along with rehabilitation, the patients showed significant improvement indicating that cell transplantation plays a vital role in the improvements. PET-CT scan was used as a monitoring tool in a small number of patients.

Conclusion {#Sec46}
==========

This study demonstrates the safety and efficacy of cell transplantation in chronic TBI on long term follow up. Early intervention of cell transplantation at young age in patients with mild TBI showed the best outcome in this study. When combined with neurorehabilitation, cell transplantation may help to improve the quality of life of patients with chronic TBI by recovering their lost functions and making them independent in activities of daily living. The clinical improvements seen in the patients correlated with the metabolic improvements on PET CT scan post cell transplantation. Hence, PET CT scan may be used to monitor the changes in the brain functions after cell transplantation.
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